Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
COUR Pharma has closed a $50 million Series B funding round led by Lumira Ventures and Roche Venture Fund, with participation from Sanofi to advance their investigational therapy CNP-103 for type 1 diabetes.
PRIVATEJun 18, 2026•about 2 months ago
Amount Raised
$50 Million
Round Type
Series B
SkokiePharmaceutical ManufacturingInvestors
T1 D Fund: A Breakthrough T1 D VentureAngelini VenturesPfizer VenturesAlpha Wave VenturesSanofiRoche Venture FundLumira Ventures
Description
COUR Pharma announced the closing of a $50 million Series B funding round with existing investors Lumira Ventures and Roche Venture Fund leading the investment and new investor Sanofi participating. The funds will support the clinical advancement of CNP-103, an investigational therapy for type 1 diabetes. Existing investors reaffirmed their support for COUR's tolerance platform. CNP-103 is currently in an active Phase 2 trial to assess its safety and efficacy.
Related People
Suggested for you
2 contactsVerified contactsStan R., Vice President of Quality hidden hidden
Funding Insights
Based on industry dataTimeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech